Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Spiriva, Spiriva Respimat, Spiriva Handihaler
tiotropium · 3 trials · 1 indication
maximum plasma concentration
measured by noncompartmental analysis
noncompartmental analysis
| Arm | Type | Description |
|---|---|---|
| Test Product 1 Tiotropium | EXPERIMENTAL | 4 inhalations |
| Test Product 2 Tiotropium | EXPERIMENTAL | 4 inhalations |
| Test Product 3 Tiotropium | EXPERIMENTAL | 4 inhalations |
| Reference Tiotropium | ACTIVE_COMPARATOR | 2 inhalations |
| Test product A | EXPERIMENTAL | tiotropium |
| Test product B | EXPERIMENTAL | tiotropium |
| reference product | ACTIVE_COMPARATOR | tiotropium |
| test product C | EXPERIMENTAL | tiotropium |
| Commercial product D | ACTIVE_COMPARATOR | tiotropium |
| commercial product E | ACTIVE_COMPARATOR | tiotropium |
| Name | Type | Description |
|---|---|---|
| Tiotropium | DRUG | - |
Inclusion Criteria: * Healthy Volunteer * Willing and able to give informed consent * Willing to withhold all alcoholic beverages for 48 hours and all xanthine- containing foods and beverages for 24 hours prior to reporting to clinic * Subjects must agree to use an adequate method of contraception ...
Tiotropium is a small molecule drug candidate that Solventum Corporation is developing. It is in Phase 1 clinical development, and the specific medical conditions it is intended to treat have not been disclosed. The program is supported by three completed Phase 1 trials conducted in healthy adult volunteers.
Tiotropium targets CHRM3, the muscarinic acetylcholine receptor M3, and acts as an antagonist at this receptor. By blocking CHRM3, tiotropium interferes with receptor signaling. This target class and mechanism are the basis for its development as a small molecule therapeutic candidate.
Tiotropium is being developed by Solventum Corporation, which trades under the ticker SOLV. The company is responsible for the clinical program, which currently consists of three completed Phase 1 pharmacokinetic trials evaluating tiotropium delivered from inhaler products.
Tiotropium is in Phase 1 clinical development. All three of its recorded trials are Phase 1 studies, and all three have been completed. There are currently no active trials listed for this program. It is an investigational drug and has not been approved by the FDA.
Tiotropium has been studied in three completed Phase 1 trials: NCT03302065, NCT02676297, and NCT02627625. These trials compared the pharmacokinetics of tiotropium delivered from test inhaler products with reference products. Together they enrolled 95 healthy adult volunteers, and NCT02676297 and NCT02627625 were conducted in the United Kingdom.